NICE rejects eribulin for breast cancer

The National Institute for Health and Clinical Excellence (NICE) has decided that eribulin (Halaven) should not be made available on the NHS.

Eribulin is not recommended for the treatment of breast cancer on the NHS | SCIENCE PHOTO LIBRARY
Eribulin is not recommended for the treatment of breast cancer on the NHS | SCIENCE PHOTO LIBRARY

The outcome was based on the side-effect profile of eribulin in comparison to other established available treatments.

Halaven is licensed for use as monotherapy in treating patients with locally advanced or metastatic breast cancer which has progressed after at minimum of two chemotherapeutic regimens.

Further information

NICE guidance on eribulin for breast cancer

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases